keyword
MENU ▼
Read by QxMD icon Read
search

ADT

keyword
https://www.readbyqxmd.com/read/28209912/detection-efficacy-of-hybrid-68-ga-psma-ligand-pet-ct-in-prostate-cancer-patients-with-biochemical-recurrence-after-primary-radiation-therapy-defined-by-phoenix-criteria
#1
Ingo Einspieler, Isabel Rauscher, Charlotte Düwel, Markus Krönke, Christoph Rischpler, Gregor Habl, Sabrina Dewes, Armin Ott, Hans-Jürgen Wester, Markus Schwaiger, Tobias Maurer, Matthias Eiber
The aim of this retrospective study was to evaluate the detection rate of Glu-NH-CO-NH-Lys-(Ahx)-[(68)Ga(HBED-CC)] ((68)Ga-PSMA ligand) positron emission tomography/computed tomography (PET/CT) in patients with biochemical recurrent prostate cancer (PC) defined by Phoenix criteria after external beam radiotherapy (EBRT) or brachytherapy as primary treatment. Methods: 118 patients were finally eligible for this retrospective analysis with a median prostate-specific antigen (PSA) of 6.4 ng/mL (range: 2.2-158...
February 16, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28209634/cognitive-decline-in-prostate-cancer-patients-undergoing-adt
#2
Niamh Liana Mundell, Robin M Daly, Helen Macpherson, Steve F Fraser
Androgen deprivation therapy (ADT) is an effective and widely prescribed treatment for prostate cancer (PCa), but it is associated with multiple treatment induced adverse effects that impact on various musculoskeletal and cardiometabolic health outcomes. Emerging research has shown that ADT is also associated with cognitive impairment, which has been linked to a loss of independence, increased falls and fracture risk and greater use of medical services. The aim of this review is to outline the evidence related to the effect of ADT use on cognitive function, and propose a role for exercise training as part of usual care to prevent and/or manage cognitive impairments for PCa survivors on ADT...
February 16, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28204918/androgen-deprivation-therapy-and-the-risk-of-parkinsonism-in-men-with-prostate-cancer
#3
James W S Young, Rinku Sutradhar, Jagadish Rangrej, Connie Marras, Neil Fleshner, Shabbir M H Alibhai
PURPOSE: Case reports and anecdotal experiences suggest that some men develop parkinsonism after initiating androgen deprivation therapy (ADT) for the treatment of prostate cancer, possibly due to neurophysiological effects of changes in testosterone and/or estrogen. We hypothesized that ADT would increase the risk of parkinsonism. METHODS: Using linked administrative databases in Ontario, Canada, men age 40 or older with prostate cancer on continuous ADT for at least 6 months or who underwent bilateral orchiectomy (n = 38,931) were matched 1:1 with men with prostate cancer who had never received ADT...
February 15, 2017: World Journal of Urology
https://www.readbyqxmd.com/read/28202212/long-term-patient-reported-urinary-function-following-external-beam-radiotherapy-for-prostate-cancer
#4
S Chin, A J Hayden, V Gebski, S Cross, S L Turner
INTRODUCTION: This study reports long-term patient reported urinary function and urinary-related quality of life (uQoL) after external beam radiotherapy (EBRT) for localized prostate cancer. METHODS: 574 men underwent definitive prostate EBRT to 70-78 Gy±androgen deprivation therapy between 2000 and 2009. The median follow-up from EBRT was 44 months. Patients were evaluated at baseline (pre-EBRT) and at intervals post-treatment using the International Prostate Symptom Score (IPSS) instrument...
February 12, 2017: Clinical Oncology: a Journal of the Royal College of Radiologists
https://www.readbyqxmd.com/read/28188757/cognitive-effects-of-androgen-deprivation-therapy-in-men-with-advanced-prostate-cancer
#5
Bulent Gunlusoy, Yasin Ceylan, Aslı Koskderlioglu, Muhtesem Gedizlioglu, Tansu Degirmenci, Pınar Ortan, Zafer Kozacioglu
OBJECTIVES: To evaluate prostate cancer effects of androgen deprivation therapy (ADT) by using a systematic set of methods to calculate specific cognitive functions in men with locally advanced or metastatic prostate cancer. METHODS: From April 2014 to February 2016, a prospective, comparative study was done to evaluate the cognitive effects of hormone therapy.Group 1 consisted of 78 patients with locally advanced or metastatic prostate cancer who received complete ADT treatment continously for 12 months and group 2 (control group) consisted of 78 patients who underwent radical prostatectomy without any additional treatment...
February 7, 2017: Urology
https://www.readbyqxmd.com/read/28185462/-options-of-chemotherapy-in-the-treatment-of-prostate-cancer
#6
I Richter, J Dvořák, J Bartoš
BACKGROUND: Prostate cancer is one of the most common malignancies in men. Chemotherapy has an important role in the management of prostate cancer, especially for the treatment of castrate resistant prostate cancer (mCRPC). According to recently published studies, chemotherapy can also be used to treat advanced hormone sensitive disease. AIM: The aim of this report is to review the currently available options for chemotherapy of prostate cancer. RESULTS: Docetaxel is a chemotherapeutic agent used for standard treatment of mCRPC as 1st line therapy...
2017: Klinická Onkologie: Casopis Ceské a Slovenské Onkologické Spolecnosti
https://www.readbyqxmd.com/read/28183253/optimal-management-of-prostate-cancer-based-on-its-natural-clinical-history
#7
Gaetano Facchini, Francesco Perri, Gabriella Misso, Carmine D Aniello, Giuseppina Della Vittoria Scarpati, Sabrina Rossetti, Chiara Della Pepa, Salvatore Pisconti, Gerhard Unteregger, Alessia Cossu, Michele Caraglia, Massimiliano Berretta, Carla Cavaliere
Prostate cancer is the most common malignancy in males and, despite a marked improvement in diagnostic techniques, a not small percentage of prostate tumours is still diagnosed in advanced stage. It is now clear that prostate cancer passes through distinct phases during its natural history, starting from an initial phase, in which the disease has a locoregional extent, until a very late phase when it becomes refractory to hormone therapy. It is important to distinguish between local disease, in which tumor may be considered localized in the gland and a systemic disease characterized by high tumor burden and/or dissemination of circulating tumour cells...
February 8, 2017: Current Cancer Drug Targets
https://www.readbyqxmd.com/read/28169490/cognitive-impairment-among-prostate-cancer-patients-an-overview-of-reviews
#8
REVIEW
C J Treanor, J Li, M Donnelly
To identify and clarify definitions and methods of measuring cancer-related cognitive impairment among prostate cancer patients treated with androgen deprivation therapy (ADT) and to assess the incidence and prevalence of cognitive impairment. A systematic review of Medline, EMBASE, PubMed, PsycINFO and CINAHL up to December 2015 was undertaken to identify English-language reviews. A total of 28 reviews were identified describing 20 primary studies. There were no studies of incidence. Reported prevalence rates varied between 10% and 69%...
February 7, 2017: European Journal of Cancer Care
https://www.readbyqxmd.com/read/28166157/223ra-dichloride-bone-targeted-therapy-in-a-case-of-metastatic-salivary-duct-carcinoma
#9
Matteo Manfredi, Mario Airoldi, Marcello Tucci, Consuelo Buttigliero, Antonella Parente, Tiziana Angusti
Salivary duct carcinoma (SDC) is a rare malignancy, frequently overexpressing androgen receptor (AR). Therefore, similar to AR-positive prostate cancer (PCa), AR-positive SDC patients benefit from androgen deprivation therapy and, after progression on ADT, might take advantage of Ra dichloride, a radiopharmaceutical approved for the treatment of castration-resistant PCa with symptomatic bone disease. We report the case of a 75-year-old man with castration-resistant SDC and osteoblastic bone metastases who, after Ra treatment, achieved adequate control of bone pain and bone lesion reduction with minor side effects...
February 3, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28163684/the-new-synthetic-h2s-releasing-sdss-protects-mc3t3-e1-osteoblasts-against-h2o2-induced-apoptosis-by-suppressing-oxidative-stress-inhibiting-mapks-and-activating-the-pi3k-akt-pathway
#10
Xiaofei Yan, Haixia Wu, Zhiyuan Wu, Fei Hua, Dong Liang, Hong Sun, Yong Yang, Dejian Huang, Jin-Song Bian
Reactive oxygen species (ROS) are important in osteoporosis development. Oxidative stress induces apoptosis of osteoblasts and arrest of their differentiation. Both Danshensu (DSS) and hydrogen sulfide (H2S) produce significant antioxidant effect in various systems. In this study, we synthesized SDSS, a novel H2S-releasing compound derived from DSS, and studied its antioxidant effect in an H2O2-induced MC3T3-E1 osteoblastic cell injury model. We first characterized the H2S releasing property of SDSS in both in vivo and in vitro models...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28159676/transformation-of-prostatic-adenocarcinoma-to-well-differentiated-neuroendocrine-tumor-after-hormonal-treatment
#11
Syed Gilani, Charles C Guo, Elsa M Li-Ning, Curtis Pettaway, Patricia Troncoso
Carcinoid tumor of the prostate is extremely rare. Here we report a unique case of prostate cancer that underwent complete transformation from conventional adenocarcinoma to carcinoid-like tumor shortly after androgen deprivation treatment (ADT). The patient was a 59years old man who presented with lower urinary tract symptoms. His biopsy specimen demonstrated a high-grade prostatic adenocarcinoma with mixed acinar and ductal features. After ADT for 6months, the patient underwent radical prostatectomy. The post-ADT tumor showed monotonous neoplastic cells with fine granular chromatin forming rosette-like structures, resembling a carcinoid tumor...
January 31, 2017: Human Pathology
https://www.readbyqxmd.com/read/28159496/androgen-deprivation-with-or-without-radiation-therapy-for-clinically-node-positive-prostate-cancer-lin-cc-gray-pj-jemal-a-efstathiou-ja-surveillance-and-health-services-research-program-intramural-research-american-cancer-society-atlanta-ga-ccl-aj-department
#12
Eggener Scott
BACKGROUND: Clinically lymph node-positive (cN+) prostate cancer (PCa) is an often-fatal disease. Its optimal management remains largely undefined given a lack of prospective, randomized data to inform practice. We sought to describe modern practice patterns in the management of cN+PCa and assess the effect of adding radiation therapy (RT) to androgen deprivation therapy (ADT) on survival using the National Cancer Data Base. METHODS: Patients with cN+PCa and without distant metastases diagnosed between 2004 and 2011 were included...
January 31, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28159490/chemohormonal-therapy-in-metastatic-hormone-sensitive-prostate-cancer-sweeney-cj-chen-yh-carducci-m-liu-g-jarrard-df-eisenberger-m-wong-yn-hahn-n-kohli-m-cooney-mm-dreicer-r-vogelzang-nj-picus-j-shevrin-d-hussain-m-garcia-ja-dipaola-rs-department-of-medicine
#13
Eggener Scott
BACKGROUND: Androgen deprivation therapy (ADT) has been the backbone of treatment for metastatic prostate cancer since the 1940s. We assessed whether concomitant treatment with ADT plus docetaxel would result in longer overall survival than that with ADT alone. METHODS: We assigned men with metastatic, hormone-sensitive prostate cancer to receive either ADT plus docetaxel (at a dose of 75mg per square meter of body-surface area every 3wk for 6 cycles) or ADT alone...
February 1, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28158241/androgen-deprivation-therapy-and-fracture-risk-in-chinese-patients-with-prostate-carcinoma
#14
Chi-Ho Lee, Gang Huang, Pak-Hei Chan, Jojo Hai, Chun-Yip Yeung, Carol Ho-Yi Fong, Yu-Cho Woo, Kwan Lun Ho, Ming-Kwong Yiu, Frankie Leung, Tak-Wing Lau, Hung-Fat Tse, Karen Siu-Ling Lam, Chung-Wah Siu
OBJECTIVE: Androgen deprivation therapy (ADT) increases fracture risk in men with carcinoma of the prostate, but little is known about the fracture risk for different types of ADT. We studied the fracture risk amongst Chinese patients with carcinoma of the prostate prescribed different ADT regimens. SUBJECTS AND METHODS: This was a single-centered observational study that involved 741 patients with carcinoma of the prostate from January 2001 to December 2011. RESULTS: After a median follow-up of 5 years, 71...
2017: PloS One
https://www.readbyqxmd.com/read/28144973/minnelide-inhibits-androgen-dependent-castration-resistant-prostate-cancer-growth-by-decreasing-expression-of-androgen-receptor-full-length-and-splice-variants
#15
Sumit Isharwal, Shrey Modi, Nivedita Arora, Charles Uhlrich, Bhuwan Giri, Usman Barlass, Ayman Soubra, Rohit Chugh, Scott M Dehm, Vikas Dudeja, Ashok Saluja, Sulagna Banerjee, Badrinath Konety
BACKGROUND: With almost 30,000 deaths per year, prostate cancer is the second-leading cause of cancer-related death in men. Androgen Deprivation Therapy (ADT) has been the corner stone of prostate cancer treatment for decades. However, despite an initial response of prostate cancer to ADT, this eventually fails and the tumors recur, resulting in Castration Resistant Prostate Cancer (CRPC). Triptolide, a diterpene triepoxide, has been tested for its anti-tumor properties in a number of cancers for over a decade...
February 1, 2017: Prostate
https://www.readbyqxmd.com/read/28139422/salvage-of-locally-recurrent-prostate-cancer-after-external-beam-radiation-using-reduced-dose-brachytherapy-with-neoadjuvant-plus-adjuvant-androgen-deprivation
#16
Brian C Baumann, John C Baumann, John P Christodouleas, Edward Soffen
PURPOSE: Local recurrence (LR) of prostate cancer after external beam radiotherapy (EBRT) is a serious problem. Our purpose was to determine if reduced-dose salvage brachytherapy could achieve high rates of biochemical control with acceptable toxicity if combined with androgen deprivation therapy (ADT). METHODS AND MATERIALS: Thirty-three consecutive patients with LR after EBRT were treated with salvage brachytherapy plus ADT from 1998 to 2013. All had pathologically confirmed LR, disease-free interval ≥18 months after EBRT, no distant/nodal metastasis, and International Prostate Symptom Score ≤15...
January 27, 2017: Brachytherapy
https://www.readbyqxmd.com/read/28134800/immune-modulation-by-androgen-deprivation-and-radiation-therapy-implications-for-prostate-cancer-immunotherapy
#17
REVIEW
Jennifer L Kalina, David S Neilson, Alexandra P Comber, Jennifer M Rauw, Abraham S Alexander, Joanna Vergidis, Julian J Lum
Prostate cancer patients often receive androgen deprivation therapy (ADT) in combination with radiation therapy (RT). Recent evidence suggests that both ADT and RT have immune modulatory properties. First, ADT can cause infiltration of lymphocytes into the prostate, although it remains unclear whether the influx of lymphocytes is beneficial, particularly with the advent of new classes of androgen blockers. Second, in rare cases, radiation can elicit immune responses that mediate regression of metastatic lesions lying outside the field of radiation, a phenomenon known as the abscopal response...
January 27, 2017: Cancers
https://www.readbyqxmd.com/read/28134791/a-tale-of-two-signals-ar-and-wnt-in-development-and-tumorigenesis-of-prostate-and-mammary-gland
#18
REVIEW
Hubert Pakula, Dongxi Xiang, Zhe Li
Prostate cancer (PCa) is one of the most common cancers and among the leading causes of cancer deaths for men in industrialized countries. It has long been recognized that the prostate is an androgen-dependent organ and PCa is an androgen-dependent disease. Androgen action is mediated by the androgen receptor (AR). Androgen deprivation therapy (ADT) is the standard treatment for metastatic PCa. However, almost all advanced PCa cases progress to castration-resistant prostate cancer (CRPC) after a period of ADT...
January 27, 2017: Cancers
https://www.readbyqxmd.com/read/28124495/very-high-risk-prostate-cancer-stratification-by-outcomes-of-radiotherapy-and-long-term-androgen-deprivation-therapy
#19
Natsuo Tomita, Norihito Soga, Yuji Ogura, Takumi Kageyama, Takeshi Kodaira
AIM: The definition of very high-risk (VHR) prostate cancer is currently based on the study of radical prostatectomy. We aimed to identify a suitable definition for VHR group following external beam radiation therapy (EBRT) and long-term androgen-deprivation therapy (ADT). METHODS: This retrospective study included 356 high-risk patients treated with EBRT and long-term ADT. A median follow-up time was 68 months. At first, associations of previously described prognostic factors with biochemical disease-free survival (bDFS), clinical relapse-free survival (cRFS) and prostate cancer-specific survival (CSS) were examined...
January 25, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28123517/role-of-free-testosterone-levels-in-patients-with-metastatic-castration-resistant-prostate-cancer-receiving-second-line-therapy
#20
Christoph A von Klot, Markus A Kuczyk, Alena Boeker, Christoph Reuter, Florian Imkamp, Thomas R W Herrmann, Hossein Tezval, Mario W Kramer, Sven Perner, Axel S Merseburger
A range of new treatment options has recently become available for patients with advanced metastatic castration-resistant prostate cancer (mCRPC). Androgen deprivation therapy (ADT) with luteinizing hormone-releasing hormone is continued when performing chemotherapy or androgen deprivation with new second-generation therapeutic agents such as enzalutamide or abiraterone acetate. Despite the fact that free testosterone (FT) is the biologically active form, it is common practice that androgen suppression is monitored via total testosterone levels only...
January 2017: Oncology Letters
keyword
keyword
58121
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"